Brokerage Firm Rating on Abbott Laboratories (ABT)

Abbott Laboratories (ABT) has an average broker rating of 1.6, which is interpreted as a Buy, as rated by 15 equity analysts. Nonetheless, 10 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Abbott Laboratories (ABT) : 11 investment research analysts covering Abbott Laboratories (ABT) have an average price target of $48.82 for the near short term. The highest target price given by the Brokerage Firm to the stock is $52 and the lowest target is $45 for the short term. Analysts expect the variance to be within $1.78 of the average price.


For the current week, the company shares have a recommendation consensus of Buy. Abbott Laboratories (NYSE:ABT): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $44.85 and $44.75 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $45.14. The buying momentum continued till the end and the stock did not give up its gains. It closed at $45.05, notching a gain of 0.54% for the day. The total traded volume was 5,756,248 . The stock had closed at $44.81 on the previous day.

In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Executive Vice President) of Abbott Laboratories, Fussell Stephen R had sold 41,500 shares worth of $1,867,915 in a transaction dated July 28, 2016. In this transaction, 41,500 shares were sold at $45.01 per share.

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.